Cord Blood Banking Market to Reach $49.8B by 2031

The blood remaining in the umbilical cord and placenta post-delivery is a rich source of hematopoietic stem cells, which can develop into various types of blood and immune system cells. This cord blood is collected, processed, and cryogenically frozen for potential future medical use. Stored cord blood does not have a definitive expiration date and may be viable for a lifetime. The first successful cord blood transplant occurred in 1988 to treat a child with Fanconi anemia, a rare genetic disease. This groundbreaking procedure demonstrated the potential of cord blood as a viable alternative to bone marrow for stem cell transplantation. Since then, cord blood stem cells have been used in the treatment of over 80 diseases, including various cancers like leukemia and lymphoma, blood disorders such as sickle cell anemia, and some immune system and metabolic disorders. Parents have the option to donate cord blood to public banks for anyone in need or to store it in private banks for their family's exclusive use. Public donation is free and encouraged by major medical organizations, while private banking involves collection and annual storage fees that can amount to thousands of dollars. As of recent data, there are over 800,000 units in public banks and more than 5 million units stored in private banks globally. The cord blood banking industry includes a mix of private companies and public initiatives. Some of the key players in the market include Cord Blood Registry (CBR) Systems Inc., Cryo-Cell International, and ViaCord. The first private cord blood bank was established in 1992, and the first public bank was launched around the same time.